Therefore, we might speculate that increased Tim-3 expression at diagnosis could be linked to high disease burden and/or to an NK cell-mediated cytotoxicity, while after treatment to an increased immune response, that might be ineffective or impaired, thus supporting the use of cobolimab as a possible salvage therapy in refractory/relapsed AML and high-risk patients. Here, HAVCR2 is linked to acute myeloid leukemia.